# Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/cannabis-use-disorder-treatment-guidelines-expert-consensus/
> **Published:** 2026-04-28T04:03:47-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:00:03-04:00
> **Clinical Summary:** British psychopharmacology experts release evidence-based guidelines for cannabis use disorder treatment and other substance dependencies in clinical practice.

---

CED Clinical Relevance  #62Notable Clinical Interest
Evidence Brief | CED ClinicBritish experts issue comprehensive evidence-based guidelines for pharmacological management of substance dependence including cannabis and synthetic cannabinoids.
[Cannabis Dependence](https://cedclinic.com/ptsd-cannabis-dependence-veterans-social-support/)[Addiction Medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/)Clinical GuidelinesPharmacotherapyEvidence-Based Medicine

British experts issue comprehensive evidence-based guidelines for pharmacological management of substance dependence including cannabis and synthetic cannabinoids.

What This Study Teaches Us

These guidelines represent a structured attempt to synthesize available evidence across multiple substance dependencies into actionable clinical recommendations. The inclusion of cannabis and synthetic cannabinoids alongside traditional substances of dependence reflects evolving clinical needs in [addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/).

Why This Matters
Clinicians managing patients with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) now have formal guidance from a respected international body. This legitimizes [cannabis dependence](https://cedclinic.com/ptsd-cannabis-dependence-veterans-social-support/) as a clinical entity requiring evidence-based pharmacological intervention alongside other substance dependencies.

Study Snapshot

Study Type
Expert Consensus Guidelines

Population
International expert panel reviewing evidence for substance dependence treatment

Intervention
Systematic review of pharmacological treatments for multiple substance dependencies

Comparator
Current evidence base across substances

Primary Outcome
Clinical recommendations for pharmacological management

Key Finding
Comprehensive guidelines developed covering alcohol, benzodiazepines, opioids, cannabis, synthetic cannabinoids, and other substances

Journal
Journal of Psychopharmacology

Year
2024

Clinical Bottom Line
The British Association for Psychopharmacology has formally recognized cannabis dependence as warranting pharmacological treatment guidelines. These recommendations provide a framework for clinical decision-making in [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) management.

What This Paper Does Not Show
The abstract does not reveal the specific pharmacological recommendations for [cannabis dependence treatment](https://cedclinic.com/cessation-of-cannabis-use-predictors/). We cannot determine the strength of evidence supporting cannabis-specific interventions or the clinical efficacy of recommended approaches.

Where This Paper Deserves Skepticism
Consensus guidelines reflect expert opinion synthesis rather than primary research data. The quality of recommendations depends entirely on the underlying evidence base, which for cannabis dependence remains limited compared to other substances.

Dr. Caplan's Take
I welcome formal recognition of cannabis use disorder in pharmacological treatment guidelines, as this validates what we see clinically. However, the pharmacological options for cannabis dependence remain quite limited compared to alcohol or opioid dependence, so I’m curious about the specific recommendations.

What a Careful Reader Should Take Away

Cannabis dependence is now included in mainstream addiction medicine guidelines alongside traditional substances. While this represents important clinical recognition, the specific treatment recommendations require review of the full guidelines to assess practical applicability.

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

Have thoughts on this? Share it:

[X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Evidence-based%20consensus%20guidelines%20for%20the%20pharmacological%20management%20of%20substance%20dependence%3A%20Reco...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-use-disorder-treatment-guidelines-expert-consensus%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-use-disorder-treatment-guidelines-expert-consensus%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Evidence-based%20consensus%20guidelines%20for%20the%20pharmacological%20management%20of%20substance%20dependence%3A%20Reco...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fcannabis-use-disorder-treatment-guidelines-expert-consensus%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/)

Table of Contents

- [FAQ](#FAQ)[What pharmacological treatments are recommended for cannabis dependence?](#What_pharmacological_treatments_are_recommended_for_cannabis_dependence)
- [How do treatment approaches differ between natural cannabis and synthetic cannabinoids?](#How_do_treatment_approaches_differ_between_natural_cannabis_and_synthetic_cannabinoids)
- [What is the strength of evidence for cannabis dependence pharmacological treatments?](#What_is_the_strength_of_evidence_for_cannabis_dependence_pharmacological_treatments)
- [Should cannabis dependence be treated differently from other substance dependencies?](#Should_cannabis_dependence_be_treated_differently_from_other_substance_dependencies)
- [Who should use these cannabis dependence treatment guidelines?](#Who_should_use_these_cannabis_dependence_treatment_guidelines)
- [Related](#Related)

## FAQ

#### What pharmacological treatments are recommended for cannabis dependence?

The British Association for Psychopharmacology guidelines provide evidence-based recommendations for managing cannabis dependence pharmacologically. However, the specific medications and treatment protocols require review of the complete guidelines, as cannabis withdrawal and dependence management often involves symptom-targeted approaches rather than FDA-approved cannabis-specific medications.

#### How do treatment approaches differ between natural cannabis and synthetic cannabinoids?

The guidelines separately address natural cannabis and synthetic cannabinoids, recognizing their distinct pharmacological profiles and clinical presentations. Synthetic cannabinoids often cause more severe and unpredictable withdrawal symptoms, potentially requiring different management strategies compared to traditional cannabis dependence.

#### What is the strength of evidence for cannabis dependence pharmacological treatments?

The guidelines systematically reviewed and graded the quality of available evidence for cannabis dependence treatments. The expert consensus process identified significant gaps in the current evidence base, highlighting the need for more robust [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) in this area.

#### Should cannabis dependence be treated differently from other substance dependencies?

These evidence-based guidelines provide specific recommendations for cannabis that differ from other substances covered, including alcohol, opioids, and stimulants. Cannabis dependence management requires tailored approaches considering its unique withdrawal syndrome and the absence of established pharmacological interventions.

#### Who should use these cannabis dependence treatment guidelines?

These guidelines are designed for clinicians involved in addiction medicine, psychiatrists, and healthcare providers managing patients with cannabis use disorders. The recommendations aim to support clinical decision-making in both specialist addiction services and general healthcare settings.

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).